Page last updated: 2024-11-12
leupyrrin a1
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
leupyrrin A1: from myxobacterium Sorangium cellulosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10908784 |
CHEMBL ID | 510851 |
MeSH ID | M0460933 |
Synonyms (2)
Synonym |
---|
leupyrrin a1 |
CHEMBL510851 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID356418 | Antifungal activity against Rhodotorula glutinis | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356423 | Inhibition of DNA synthesis in Rhodotorula glutinis assessed as inhibition of [methyl-3H]thymine incorporation at 2.5 ug/mL after 30 mins | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356417 | Antifungal activity against Candida albicans | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356420 | Antifungal activity against Botrytis cinerea | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356424 | Inhibition of RNA synthesis in Rhodotorula glutinis assessed as inhibition of [2-14C]uracil incorporation at 2.5 ug/mL after 30 mins | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356419 | Antifungal activity against Aspergillus niger | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356422 | Cytotoxicity against mouse L929 cells | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356425 | Inhibition of protein synthesis in Rhodotorula glutinis assessed as inhibition of [U-14C]protein hydrolysate incorporation at 2.5 ug/mL after 30 mins | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
AID356421 | Antifungal activity against Mucor hiemalis | 2003 | Journal of natural products, Sep, Volume: 66, Issue:9 | The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.75) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (14.29%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (85.71%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |